NTRK1 and cancer: Docking score of the identified compounds against Cyclin-Dependent Kinase 2 (PDB ID: 2A4L), Tubulin (PDB ID: 1AS0), and Epidermal Growth Factor Receptor tyrosine kinase (PDB ID: 1M17) for anti-cancer activity.